CORRECTING and REPLACING Heart Rhythm Case Reports Publishes Notable Case Detailing First Use of AI-Guided ECG Mapping for Left Bundle Branch Area Pacing
SAN DIEGO, April 03, 2025--(BUSINESS WIRE)--In the release dated April 1, 2025, the quote from, and photo of, Dr. Ulrika Birgersdotter-Green has been removed.
The updated release reads:
HEART RHYTHM CASE REPORTS PUBLISHES NOTABLE CASE DETAILING FIRST USE OF AI-GUIDED ECG MAPPING FOR LEFT BUNDLE BRANCH AREA PACING
Case Report Demonstrates How vMap Enhances Accuracy and Reduces Risk in Pacemaker Implantation
Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the publication of a groundbreaking case in Heart Rhythm Case Reports. Conducted by physicians from the University of California San Diego (UCSD), the case details the first successful use of AI-enabled ECG mapping to guide left bundle branch area pacing (LBBAP) implantation. Findings highlight how vMap, a non-invasive AI-powered mapping technology, enhances procedural efficiency, accuracy, and patient safety during LBBAP lead positioning.
As LBBAP becomes a preferred physiologic pacing technique, vMap has the potential to offer a transformative approach by reducing fluoroscopy exposure and eliminating the need for contrast agents - critical factors in enhancing patient safety and procedural outcomes.
The patient in the case report, a 90-year-old male with advanced chronic kidney disease and a severe iodinated contrast allergy, underwent a dual-chamber LBBAP implantation as physicians used vMap for peri-procedural AI-driven guidance. The procedure was completed successfully with minimized fluoroscopy time and without contrast injection, mitigating risks associated with traditional approaches for the patient and physician.
Procedure Highlights:
vMap provided peri-procedural, AI-driven guidance to position the lead accurately on the RV septum.
vMap compared the patient's QRS morphology with a digital reference library of thousands of cardiac simulations of right ventricular pacing, helping localize the lead tip within the heart.
Successful lead placement was achieved with confirmed left bundle capture, reducing reliance on traditional fluoroscopic imaging.
vMap's ability to store and analyze paced QRS morphology enabled more efficient mapping, particularly in cases where the ideal pacing site was not immediately encountered.
The case report underscores vMap's ability to transform cardiac pacing workflows while prioritizing patient safety. As the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias and analyzing atrial and ventricular pacing via a standard 12-lead ECG, vMap represents a significant advancement in electrophysiology.
"This case is the first time vMap has been used to help guide LBBAP implantation. In addition to the positive procedural benefits, it's a very clear demonstration of the potential for vMap to more broadly improve cardiac care and advance various cardiac interventions," said Rob Krummen, CEO of Vektor Medical.
For more information on Vektor Medical and vMap, visit www.vektormedical.com and connect on LinkedIn and X.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401431132/en/
Contacts
Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@levitatenow.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
8 minutes ago
- WebMD
RSV Vaccine Age 50+: What a New CDC Update Means for You
July 3, 2025 – The CDC published a new recommendation this week calling for some adults ages 50 to 59 to get vaccinated for respiratory syncytial virus (RSV). Public health experts predict that if 20% of all newly eligible U.S. adults get vaccinated, it would prevent about 5,200 hospitalizations, 1,100 ICU stays, and 333 deaths annually. Here's what you should know, and what the new recommendation means for you. What is the RSV vaccine? Three versions are approved by the FDA: Pfizer's Abrysvo, GSK's Arexvy, and Moderna's mRESVIA. Any of these can protect you against respiratory syncytial virus, which infects the lungs and respiratory tract. Most RSV cases are mild, but they can be serious in children, older adults, and people with compromised immune systems. Who is the new recommendation for? Adults ages 50 to 59 with certain medical conditions, or who live in a nursing home or rural community with limited medical care access. Who was the vaccine already recommended for? Adults ages 60 to 74 with risk factors, and all people ages 75 and older. The vaccine is also recommended for people who are between 32 and 36 weeks of pregnancy during RSV season (from September through January), to protect newborns during their first RSV season. Why did the recommended age change? Federal health officials updated the recommendation because new evidence supports RSV vaccination for adults in the 50-59 age group who have health conditions. This change comes after a previous call for more research – particularly on potential risks like Guillain-Barré syndrome (a neurological condition). The latest data shows that vaccination reduces a person's risk of hospitalization due to RSV by 75%, leading health officials to conclude that the benefits outweigh the risks for the newly recommended age group. I already got an RSV vaccine. Should I get another one this year? No, RSV is a not an annual vaccine. When should I get the RSV shot? The best time for adults to get an RSV vaccine is late summer or early fall, the CDC says, but it's OK to get it at any time, such as during your routine physical appointment. The optimal months are August through October, before the rise of respiratory viruses during late fall and winter. I ' m over 50 and haven ' t gotten an RSV vaccine before. How do I know if I should get one? If you're 75 or older, the CDC recommends you get vaccinated against RSV. If you're between 50 and 74, you may be eligible if you're at high risk of severe RSV illness. Talk to your doctor, or if you know you have certain risk factors, you can ask for the vaccine. These risk factors include: Chronic cardiovascular disease (heart failure, coronary artery disease, congenital heart disease) Chronic lung or respiratory disease, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, interstitial lung disease, and cystic fibrosis End-stage renal disease or dependence on hemodialysis or other renal replacement therapy Type 1 or type 2 diabetes complicated by chronic kidney disease, neuropathy, retinopathy, or other end-organ damage Type 1 or type 2 diabetes requiring treatment with insulin or a sodium-glucose cotransporter 2 (SGLT2) inhibitor Neurologic or neuromuscular conditions that impair breathing (post-stroke dysphagia, amyotrophic lateral sclerosis, muscular dystrophy) Chronic liver disease, such as cirrhosis Chronic hematologic conditions, such as sickle cell disease or thalassemia Severe obesity (body mass index of 40 or higher) A compromised immune system Residence in a nursing home Other chronic medical conditions or risk factors a doctor believes could increase the risk of severe disease due to viral respiratory infection (such as frailty, a potentially undiagnosed medical condition, or living in a rural community with limited medical care access)
Yahoo
20 minutes ago
- Yahoo
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Year to date, REGN's shares have lost 22.9% compared with the industry's 0.6% decline. Image Source: Zacks Investment Research The approval was based on positive results from the phase I/II LINKER-MM1 trial, wherein Lynozyfic demonstrated one of the highest objective response rates (70%) and complete response rates (45%) among bispecific antibodies for this challenging patient population. With the FDA approval, Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. MM remains the second most common blood cancer, with more than 36,000 new cases expected in the US in 2025 is tailored for patients who have undergone at least four prior treatment regimens, addressing a critical unmet need in late-stage MM. The approval strengthens REGN's oncology portfolio. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. We note that the FDA had earlier issued a CRL for the BLA for linvoseltamab in R/R multiple myeloma. The sole approvability issue identified was related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo, indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. REGN's oncology franchise received a boost with the European Commission's approval of odronextamab in 2024 for treating adult patients with R/R follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono. However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its BLA for odronextamab in 2024. The FDA has accepted for review the resubmission of the BLA for odronextamab in R/R follicular lymphoma with a target action date of July 30, 2025. The successful development of these oncology drugs should be a great boost for REGN. The decline in lead drug Eylea sales is a concern for REGN. Eylea sales are under pressure due to competition from Roche's RHHBY Vabysmo. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The uptake of Vabysmo has been outstanding, causing a loss of market share for Eylea. REGN currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.69 to $8.81 over the past 60 days. EPS estimates for 2026 have jumped 12 cents to $9.12 during this time frame. The stock has risen 30.2% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same time frame. Year to date, shares of Bayer have surged 60%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
The Hill
an hour ago
- The Hill
FDA upgrades blueberry recall to highest risk level
The Food and Drug Administration (FDA) upgraded a blueberry recall this week to the highest risk level amid concerns of contamination. The FDA raised the recall of 400 boxes that weigh 30 pounds to Class I. The blueberry recall, which took place on June 9, was initiated after Alma Pak International LLC of Alma, Ga. received a positive result of Listeria monocytogenes during routine testing, according to the FDA. FDA's Class I classification is a 'situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.' The firm shipped the blueberries to one customer in North Carolina. The number of the recall is H-0204-2025. Listeria is a bacteria that can contaminate 'many foods,' according to the Centers for Disease Control and Prevention (CDC). People who consume those foods can be infected with the bacteria. The infections are rare, but can be serious, the CDC noted. Pregnant women, newborns, adults over the age of 65 and people with weak immune systems can be especially harmed if infected, according to the CDC. CDC estimates that 1,600 people are infected with Listeria each year in the United States and 260 people die from the infection. In early February, around 2 million donuts and along with other baked goods, were recalled due to listeria contamination.
